Genetic and evolutionary analysis of SARS-CoV-2 circulating in the region surrounding Islamabad, Pakistan.


Journal

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
ISSN: 1567-7257
Titre abrégé: Infect Genet Evol
Pays: Netherlands
ID NLM: 101084138

Informations de publication

Date de publication:
10 2021
Historique:
received: 26 03 2021
revised: 08 07 2021
accepted: 11 07 2021
pubmed: 17 7 2021
medline: 14 9 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

Genomic epidemiology of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has provided global epidemiological insight into the COVID-19 pandemic since it began. Sequencing of the virus has been performed at scale, with many countries depositing data into open access repositories to enable in-depth global phylogenetic analysis. To contribute to these efforts, we established an Oxford Nanopore Technologies (ONT) sequencing capability at the National Institutes of Health (NIH), Pakistan. This study highlights multiple SARS-CoV-2 lineages co-circulating during the peak of a second COVID-19 wave in Pakistan (Nov 2020-Feb 2021), with virus origins traced to the United States of America and Saudi Arabia. Ten SARS-CoV-2 positive samples were used for ONT library preparation. Sequence and phylogenetic analysis determined that the patients were infected with lineage B.1.1.250, originally identified in the United Kingdom and Bangladesh during March and April of 2020, and in circulation until the time of this study in Europe, USA and Australia. Lineage B.1.261 was originally identified in Saudi Arabia with widespread local dissemination in Pakistan. One sample clustered with the parental B.1 lineage and the other with lineage B.6 originally from Singapore. In the future, monitoring the evolutionary dynamics of circulating lineages in Pakistan will enable improved tracing of the viral spread, changing trends of their expansion trajectories, persistence, changes in their demographic dynamics, and provide guidance for better implementation of control measures.

Identifiants

pubmed: 34271187
pii: S1567-1348(21)00301-4
doi: 10.1016/j.meegid.2021.105003
pmc: PMC8277555
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105003

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Références

Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19359-64
pubmed: 22084096
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Lancet Reg Health West Pac. 2021 Feb;7:100104
pubmed: 33615284
J Hosp Infect. 2017 Feb;95(2):207-213
pubmed: 28153558
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Curr Biol. 2011 Aug 9;21(15):1251-8
pubmed: 21737280
Lancet Infect Dis. 2015 Mar;15(3):320-6
pubmed: 25619149
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1139-1145
pubmed: 32444393
Int J Infect Dis. 2021 Feb;103:282-287
pubmed: 33259879
Euro Surveill. 2021 Dec;26(49):
pubmed: 34886945
Science. 2020 Oct 30;370(6516):571-575
pubmed: 32913002
PLoS Comput Biol. 2009 Sep;5(9):e1000520
pubmed: 19779555
Nature. 2017 Apr 20;544(7650):309-315
pubmed: 28405027
J Virol. 2012 Jan;86(1):11-8
pubmed: 22013031
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
Brief Bioinform. 2019 Jul 19;20(4):1160-1166
pubmed: 28968734
Syst Biol. 2019 Nov 1;68(6):1052-1061
pubmed: 31034053
Nature. 2017 Jun 15;546(7658):401-405
pubmed: 28538723
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
MMWR Morb Mortal Wkly Rep. 2003 May 9;52(18):405-11
pubmed: 12807088

Auteurs

Sana Tamim (S)

Department of Virology/Immunology, National Institute of Health, Park Road, Chak Shahzad, Islamabad 45500, Pakistan. Electronic address: s.tamim@nih.org.pk.

Nidia S Trovao (NS)

Fogarty International Centre, National Institute of Health, Bethesda, MD, USA.

Peter Thielen (P)

Johns Hopkins University Applied Physics Laboratory, USA.

Tom Mehoke (T)

Johns Hopkins University Applied Physics Laboratory, USA.

Brian Merritt (B)

Johns Hopkins University Applied Physics Laboratory, USA.

Aamer Ikram (A)

Department of Virology/Immunology, National Institute of Health, Park Road, Chak Shahzad, Islamabad 45500, Pakistan.

Muhammad Salman (M)

Department of Virology/Immunology, National Institute of Health, Park Road, Chak Shahzad, Islamabad 45500, Pakistan.

Muhammad Masroor Alam (MM)

WHO Regional Reference Laboratory, Polio eradication Initiative, National Institute of Health, Islamabad, Pakistan.

Massab Umair (M)

Department of Virology/Immunology, National Institute of Health, Park Road, Chak Shahzad, Islamabad 45500, Pakistan.

Nazish Badar (N)

Department of Virology/Immunology, National Institute of Health, Park Road, Chak Shahzad, Islamabad 45500, Pakistan.

Adnan Khurshid (A)

WHO Regional Reference Laboratory, Polio eradication Initiative, National Institute of Health, Islamabad, Pakistan.

Nayab Mehmood (N)

WHO Regional Reference Laboratory, Polio eradication Initiative, National Institute of Health, Islamabad, Pakistan.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH